RxDoctor Payments Data

John Liao, MD

Gynecologic Oncology · Seattle, WANPI 1730389057

Payments from drug & device makers

What this record shows

This record is dominated by education: $33 of the $52 with a category attached, or 62.3%. Merck accounts for 62.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gynecologic oncology clinicians in WA, where the typical reported total is $778.

$52in general payments, 2019–2025

Across 4 payments — averaging $13.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$33
  • AstraZeneca$20
$4,949,651in research payments, 2019–2025

Across 42 payments — averaging $117,849 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$4.2M
  • AstraZeneca$646K
  • Genentech, Inc.$84K
  • Regeneron$26K
  • Sanofi US Services Inc.$13K

What the payments were for

  • Food & beverage$2038%
  • Education$3362%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck3$33
AstraZeneca1$20

How this compares

$52 in reported general payments places this provider in the 10th percentile of 36 gynecologic oncology providers in Washington.

See all gynecologic oncology providers in Washington

Medicare billing

Part B allowed, 2024
$19,244
Medicare patients
42
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →